Literature DB >> 3690523

Semiautomated colorimetric assay for in vitro screening of anticancer compounds.

R L Ruben1, R H Neubauer.   

Abstract

An in vitro tetrazolium dye (MTT) reduction technique was modified and evaluated for use in the large-scale screening of anticancer compounds by examining the activity of ten clinically used drugs against 16 different human and murine cell populations. Cell populations included colon and mammary adenocarcinomas, melanomas, leukemias, and freshly isolated normal cells. Cell lines were grown in microtiter plates for 18-20 hours prior to a 72-hour continuous exposure to the drugs. Cultures were initiated at cell densities which maximized both the difference in dye reduction and the number of cell doublings between the beginning and end of the drug exposure period. Drug potency, expressed as the 50% inhibitory concentration (IC50), was comparable whether the effect on cell doublings or dye reduction was determined. There was good agreement between this method and the more labor-intensive, conventional method of counting trypan blue dye-excluding cells in a hemacytometer. Implemented as a large-scale, high-capacity system, our adaptation of the MTT technique is a rapid, sensitive, reproducible first-line screening device for detecting anticancer compounds with cytostatic or cytocidal activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3690523

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

1.  Comparison of tetrazolium colorimetric and [3H]-uridine assays for in vitro chemosensitivity testing.

Authors:  C H Ford; V J Richardson; G Tsaltas
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; R Schönmayr; W Schachenmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

3.  Cytotoxicity of synthetic racemic ptilocaulin: a novel cyclic guanidine.

Authors:  R L Ruben; B B Snider; F W Hobbs; P N Confalone; B A Dusak
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

4.  Accurate non-invasive image-based cytotoxicity assays for cultured cells.

Authors:  Patricia Marqués-Gallego; Hans den Dulk; Claude Backendorf; Jaap Brouwer; Jan Reedijk; Julian F Burke
Journal:  BMC Biotechnol       Date:  2010-06-17       Impact factor: 2.563

5.  Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines.

Authors:  Aied M Alabsi; Siti Aishah Abu Bakar; Rola Ali; Abdul Rahman Omar; Mohd Hair Bejo; Aini Ideris; Abdul Manaf Ali
Journal:  Int J Mol Sci       Date:  2011-11-30       Impact factor: 5.923

6.  Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates.

Authors:  P E Pizao; D M Lyaruu; G J Peters; J van Ark-Otte; B Winograd; G Giaccone; H M Pinedo
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

7.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Authors:  C A Hills; L R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

8.  The MTT assay underestimates the growth inhibitory effects of interferons.

Authors:  S A Jabbar; P R Twentyman; J V Watson
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

9.  Chemosensitivity testing of small cell lung cancer using the MTT assay.

Authors:  B G Campling; J Pym; H M Baker; S P Cole; Y M Lam
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

10.  Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.

Authors:  M Samadi-Baboli; G Favre; P Canal; G Soula
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.